Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 417.29 Mil Enterprise Value: 405.82 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Sangamo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 01:30PM GMT
Release Date Price: $1.29 (-0.54%)
Luca Issi
RBC Capital Markets - Analyst

Yeah. Luca Issi, senior biotech analyst here at RBC Capital Market. And today is our great privilege to have Sangamo Therapeutics with us for a fireside chat. Representing the company, we have Sandy Macrae, Chief Executive Officer. Sandy, thanks so much for joining us. How are you doing today?

Sandy Macrae
Sangamo Therapeutics, Inc. - CEO

It's my pleasure, Luca. Great to be here.

Questions & Answers

Luca Issi
RBC Capital Markets - Analyst

Fantastic. We have a long list of questions here, but maybe before we talk about individual program, it will be great if you can just talk big picture about what progress has the organization made over the last few months, and most importantly, what's ahead of here for Sangamo?

Sandy Macrae
Sangamo Therapeutics, Inc. - CEO

So we're making great progress. Sangamo is a fascinating company. We have three things that are in late-phase development with our friends at Pfizer, where we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot